<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15698">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118378</url>
  </required_header>
  <id_info>
    <org_study_id>#4839</org_study_id>
    <secondary_id>R01MH072383-01</secondary_id>
    <secondary_id>DAHBR 9A-ASNM</secondary_id>
    <nct_id>NCT00118378</nct_id>
  </id_info>
  <brief_title>Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS</brief_title>
  <official_title>Modafinil Treatment for Fatigue in HIV+ Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether modafinil (ProvigilÂ®), a medication approved for the
      treatment of narcolepsy, is effective in reducing fatigue in adults with HIV/AIDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatigue is a common problem for many people with HIV/AIDS, interfering with daily activities
      and serving as a significant barrier to working among those whose health is otherwise stable
      or restored by antiretroviral (ARV) medication. Fatigue in HIV is associated with disability
      and diminished quality of life. It may be caused by ARVs or by the virus itself. This study
      will determine if modafinil can reduce fatigue in HIV/AIDS patients.

      This study will last 12 weeks. Participants will be randomly assigned to receive either
      modafinil or placebo daily for 4 weeks. Participants who show an improvement in symptoms
      will receive modafinil for an additional 8 weeks. Participants who do not respond to
      modafinil will have the opportunity to receive other drug treatments. All participants will
      have weekly study visits for the first 4 weeks of the study and biweekly visits for the
      remainder of the study. At each visit, participants will complete various tasks to determine
      cognitive function and self-report scales will be used to determine symptoms of depression
      and fatigue.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Fatigue Severity Scale (FSS)</measure>
    <time_frame>Measured at baseline and Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9 to 63, with a higher value indicating greater impairment due to fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Role Function Scale Outcome</measure>
    <time_frame>Measured at baseline and Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Role Function Scale includes 10 items drawn from the Short Form 36-item Health Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10 to 50.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Measured at baseline and Week 4</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>CD4 cell count is a laboratory marker providing an indication of immune functioning. Blood was drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of &gt;= 100 cells. A higher number is associated with better immune functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV RNA Viral Load</measure>
    <time_frame>Measured at baseline and Week 4</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50-100,000 copies), this measure is presented in log10. We entered the log10 value of 1.69 when the laboratory result stated &quot;under 50 copies,&quot; which was the assay's lowest limit of detectability during the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>HIV Infections</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take modafinil for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take placebo for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>50 mg per day, increasing to 200 mg per day as clinically indicated</description>
    <arm_group_label>Modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg per day, increasing to 200 mg per day as clinically indicated</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 18-75

          2. HIV+

          3. Clinically significant fatigue (score of 4.5+ on Fatigue Severity Scale, plus
             impairment on 1+ categories of Role Function Scale)

          4. Fatigue duration for 3+ months

          5. English-speaking

          6. Able to give informed consent

          7. Fecund women uses barrier method of contraception

        Exclusion Criteria:

          1. Primary care doctor does not approve of study participation

          2. Unstable medical condition (e.g. liver failure;cirrhosis, new onset opportunistic
             infection [O.I.] in past month)

          3. Untreated hypogonadism, except for men for whom testosterone replacement is medically
             contraindicated (serum testosterone below the reference range)

          4. Untreated hypothyroidism (thyroid stimulating hormone [TSH] over 5 IUI/mL)

          5. Untreated and uncontrolled hypertension

          6. Clinically significant anemia (hematocrit &lt;30%)

          7. Started testosterone or nandrolone in past 6 weeks

          8. Started or changed an antiretroviral regimen in past 4 weeks if fatigue predated the
             change; otherwise, started or changed regimen in past 2 months

          9. Untreated or under-treated major depressive disorder

         10. Started antidepressant medication within past 6 weeks

         11. Substance abuse/dependence (past 4 months)

         12. Regular and frequent cannabis use (&gt; twice/week regularly)

         13. Currently clinically significant suicidal ideation or Hamilton Depression Rating
             Scale (HAM-D) &gt;24

         14. History or current psychosis or bipolar disorder

         15. Pregnant or breastfeeding

         16. Significant untreated insomnia (score &gt;3 on HAM-D insomnia items)

         17. Currently taking psychostimulant medication or past nonresponse to modafinil

         18. Has no alternative viable antiretroviral regimen after the current one

         19. Left ventricular hypertrophy; mitral valve prolapse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith G. Rabkin, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00737204?term=rabkin&amp;rank=4</url>
    <description>Click here for a related study currently recruiting participants.</description>
  </link>
  <reference>
    <citation>Rabkin JG, McElhiney MC, Rabkin R, Ferrando SJ. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry. 2004 Dec;65(12):1688-95.</citation>
    <PMID>15641875</PMID>
  </reference>
  <results_reference>
    <citation>Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ. Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. J Clin Psychiatry. 2010 Jun;71(6):707-15. doi: 10.4088/JCP.09m05171bro. Epub 2010 May 4.</citation>
    <PMID>20492840</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>June 6, 2014</lastchanged_date>
  <firstreceived_date>July 6, 2005</firstreceived_date>
  <firstreceived_results_date>January 3, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Modafinil</keyword>
  <keyword>Depression</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled from January 2005 until December 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Modafinil</title>
          <description>Participants will take modafinil for 4 weeks. If responsive, participants will be offered 8 additional weeks of modafinil.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will take placebo for 4 weeks, if not responsive, a 12-week course of modafinil will be offered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modafinil</title>
          <description>Participants will take modafinil for 4 weeks. If responsive, participants will be offered 8 additional weeks of modafinil.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will take placebo for 4 weeks, if not responsive, a 12-week course of modafinil will be offered.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="115"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="113"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.94" spread="9.35"/>
                <measurement group_id="B2" value="45.74" spread="8.57"/>
                <measurement group_id="B3" value="45.84" spread="8.96"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="54"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="115"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fatigue Severity Scale (FSS)</title>
        <description>The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9 to 63, with a higher value indicating greater impairment due to fatigue.</description>
        <time_frame>Measured at baseline and Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The WEEK 4 outcome analyses are based on an intention to treat sample which includes the 10 dropouts (2 on Modafinil and 8 on Placebo), using the last data point brought forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Participants randomized to modafinil for 4 weeks. If responsive, participants will be offered 8 additional weeks of modafinil.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to placebo for 4 weeks, if not responsive, a 12-week course of modafinil will be offered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="53"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Fatigue Severity Scale (FSS)</title>
            <description>The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9 to 63, with a higher value indicating greater impairment due to fatigue.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline FSS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52" spread="7"/>
                  <measurement group_id="O2" value="52" spread="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 FSS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34" spread="5"/>
                  <measurement group_id="O2" value="43" spread="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Role Function Scale Outcome</title>
        <description>The Role Function Scale includes 10 items drawn from the Short Form 36-item Health Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10 to 50.</description>
        <time_frame>Measured at baseline and Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>The WEEK 4 outcome analyses are based on an intention to treat sample which includes the 10 dropouts (2 on Modafinil and 8 on Placebo), using the last data point brought forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Participants randomized to modafinil for 4 weeks. If responsive, participants will be offered 8 additional weeks of modafinil.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to placebo for 4 weeks, if not responsive, a 12-week course of modafinil will be offered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="53"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Role Function Scale Outcome</title>
            <description>The Role Function Scale includes 10 items drawn from the Short Form 36-item Health Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10 to 50.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Role Function Scale</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39" spread="7"/>
                  <measurement group_id="O2" value="36" spread="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 Role Function Scale</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22" spread="9"/>
                  <measurement group_id="O2" value="27" spread="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Cell Count</title>
        <description>CD4 cell count is a laboratory marker providing an indication of immune functioning. Blood was drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of &gt;= 100 cells. A higher number is associated with better immune functioning.</description>
        <time_frame>Measured at baseline and Week 4</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Results were included for patients on whom baseline and week 4 labs were drawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Participants randomized to modafinil for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to placebo for 4 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>CD4 Cell Count</title>
            <description>CD4 cell count is a laboratory marker providing an indication of immune functioning. Blood was drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of &gt;= 100 cells. A higher number is associated with better immune functioning.</description>
            <units>Cells/mcL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline CD4 cell count</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="481" spread="249"/>
                  <measurement group_id="O2" value="459" spread="257"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 CD4 cell count</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="466" spread="244"/>
                  <measurement group_id="O2" value="482" spread="240"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&gt;= .24</p_value>
            <method>Paired t-tests</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV RNA Viral Load</title>
        <description>HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50-100,000 copies), this measure is presented in log10. We entered the log10 value of 1.69 when the laboratory result stated &quot;under 50 copies,&quot; which was the assay's lowest limit of detectability during the study.</description>
        <time_frame>Measured at baseline and Week 4</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Results were included for patients on whom baseline and week 4 labs were drawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Participants randomized to modafinil for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to placebo for 4 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>HIV RNA Viral Load</title>
            <description>HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50-100,000 copies), this measure is presented in log10. We entered the log10 value of 1.69 when the laboratory result stated &quot;under 50 copies,&quot; which was the assay's lowest limit of detectability during the study.</description>
            <units>Log10 copies/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Log10 Viral Load</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.53" spread="1.2"/>
                  <measurement group_id="O2" value="2.41" spread="1.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 Log10 Viral load</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.31" spread="1.0"/>
                  <measurement group_id="O2" value="2.30" spread="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>.052</p_value>
            <method>Paired t-tests</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weeks 1-4 during the double-blind phase of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Modafinil</title>
          <description>Participants will take modafinil for 4 weeks. If responsive, participants will be offered 8 additional weeks of modafinil.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will take placebo for 4 weeks, if not responsive, a 12-week course of modafinil will be offered.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was conducted at a single site in an urban setting where most patients have good access to medical care. Women were under-represented despite outreach efforts.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Judith Rabkin</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>212.543.5762</phone>
      <email>jgr1@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
